8 April 2014Americas

Teva asks US Supreme Court to stay ruling in Copaxone case

Teva has filed an application with the US Supreme Court to stay a ruling by the US Court of Appeals for the Federal Circuit that allowed generic drug makers to enter the market before the expiry of Teva’s patents covering its $4.3 billion-a-year multiple sclerosis drug Copaxone (glatiramer acetate).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

$5.4bn medtech leader fails to bury a rival's patent

19 January 2026 An Israeli medical device company’s lawsuit claims Edwards knowingly infringed its heart-valve patent, raising new risks as the giant pursues growth beyond its core market.

Americas

ITC to probe Oura Ring after Samsung retaliates, seeking import ban

15 January 2026 The wearable tech fight continues as Samsung seeks to block US sales of the Finnish brand's product after being sued over its Galaxy Ring.

Americas

Speciality pharma firm stumbles on bid to enforce Belbuca ruling

15 January 2026 A court has blocked the patent owner's latest attempt to stop a generic rival as it weighs the right way to challenge a new product.